(PROF) Profound Medical Corp. Business Model Canvas Research

Profound Medical Corp. uses regional distributors and commercial agents in Canada, Germany, the United States, and Finland to sell, install, and support its systems. With 4 key markets covered through local partners, the model lowers country-by-country market access work and speeds hospital rollout.

• 4 active markets
• Local selling and installation
• Lower market access complexity

Profound Medical Corp depends on regulators, hospitals, and payers because MR-guided ablation only scales when approvals, quality rules, and payment codes align. In the U.S., Medicare covered about 66 million people in 2025, so even small coverage changes can move procedure volume and hospital adoption.

These stakeholders shape both access and economics: hospital capital budgets affect MR suite rollout, while payer reimbursement decides if TULSA can be used beyond niche centers.

• Approvals set where use is allowed
• Coverage drives procedure volume
• Hospitals decide MR suite adoption

Profound Medical Corp.’s systems are deployed in hospitals, so installation and clinician training are part of the sale, not an afterthought. The company’s service team keeps MRI-guided therapy workflows running, which supports higher uptime, more procedures, and better customer retention.

In practice, this means onboarding surgeons, radiology staff, and nurses on MRI-guided use so procedures are done safely and consistently. Ongoing support also protects utilization, which matters because each system’s value depends on repeat case volume.

• Hospital install and onboarding are required.
• Training supports safe MRI-guided use.
• Service helps uptime and retention.

Profound Medical Corp. must keep a quality system aligned with ISO 13485 and FDA 21 CFR 820, while clearing products for each market under rules like the EU MDR 2017/745. These controls cover design files, complaint handling, and post-market surveillance, which helps protect access across multiple jurisdictions and lowers the risk of recalls or launch delays.

• ISO 13485 quality system
• FDA and EU clearance files
• Post-market complaint controls

Profound Medical Corp. key resource is clinical and regulatory evidence: without proof of safety and effectiveness, hospitals move slower and physicians trust less. Its TULSA-PRO platform has FDA De Novo clearance and CE mark, and that kind of documentation is what supports purchasing, reimbursement talks, and entry into new countries.

• Drives hospital buying decisions
• Builds physician confidence
• Supports multi-country market access

Profound Medical Corp. runs its core operations from Mississauga, Canada, and uses subsidiaries to support sales, service, and market access outside Canada. This structure helps coordinate global execution for a company that reported 2024 revenue of US$12.6 million and continued building international commercialization capacity.

• Mississauga is the operating hub
• Subsidiaries support global commercialization
• Central structure helps align execution

Sonalleve extends Profound Medical Corp.’s portfolio into palliative oncology by treating pain linked to bone metastases, a condition seen in up to 70% of patients with advanced breast, prostate, or lung cancer. The value proposition is clear: non-invasive symptom relief and better quality of life for patients who need pain control, not curative treatment.

• Palliative oncology use case
• Pain relief for bone metastases
• Supports quality of life

Profound Medical Corp.’s MRI-guided systems fit into MRI scanners already in treatment centers, so hospitals can add therapy without building a new imaging suite. That lowers capital spend and makes adoption easier because it uses existing 1.5T/3T MRI assets and staff workflows already in place.

• Uses existing hospital MRI scanners
• Reduces new infrastructure needs
• Lowers adoption friction for centers

Physician education is a key customer relationship for Profound Medical Corp because adoption in medtech depends on clinical awareness. Training helps doctors understand TULSA-PRO indications, workflow, and outcomes, while evidence sharing can speed center-level uptake and repeat use.

• Builds clinical awareness fast
• Clarifies patient selection and workflow
• Uses evidence to lift site adoption

That support shortens the learning curve and helps each new center move from trial to routine use.

Profound Medical Corp.’s TULSA-PRO use in specialized centers supports long-term institutional partnerships because hospitals can build recurring procedure volume instead of one-off sales. That setup favors multi-year contracts, repeat orders, and broader rollout across treatment networks as each center adds more eligible patients.

• Recurring use in specialty centers

• Supports multi-year hospital ties

• Drives repeat business and account expansion

Medical conferences and specialty meetings are a key channel for Profound Medical Corp. Major events like the AUA Annual Meeting draw 10,000+ attendees, while ASCO reaches 40,000+ oncology professionals, giving strong exposure to urology, gynecology, and oncology buyers. They help train physicians, build credibility, and generate qualified leads.

• High-value physician education
• Direct access to specialty stakeholders
• Credibility plus lead generation

Service and support teams are a key delivery channel for Profound Medical Corp, covering installation, troubleshooting, and ongoing use of its image-guided therapy systems. Strong technical support helps protect uptime, lifts customer satisfaction, and can drive referrals, which matters as the company scales recurring clinical use.

• Install and train users
• Fix issues fast
• Support daily clinical use
• Lift satisfaction and referrals

Oncology and pain management centers are a clear Customer Segment for Profound Medical Corp because Sonalleve also supports palliative pain relief for bone metastases, a condition that affects up to 70% of patients with advanced breast or prostate cancer. These teams focus on symptom control and quality of life, and they make buying calls around low-risk, non-opioid pain care.

• Bone metastases are common in advanced cancer.
• Care teams prioritize comfort and function.
• Sonalleve fits palliative pain pathways.

Academic medical centers and treatment networks are the first stop for complex systems like Profound Medical Corp.'s TULSA-PRO, because teaching hospitals can run early protocols, build peer-reviewed evidence, and create reference cases. These sites also speed spread into regional care systems, where one flagship center can train many downstream physicians.

• Early clinical evidence
• Reference cases for peers
• Faster regional rollout

Profound Medical Corp. needs a sales force in 4 countries, and marketing, demos, and field application support are recurring costs that rise as the Company adds sites and procedures. In this model, these expenses are tied to commercialization scale, so faster market expansion usually means higher selling costs before volume catches up.

• 4-country sales footprint
• Recurring demo and support spend
• Costs scale with expansion

Profound Medical Corp. carries fixed regulatory, quality, and corporate overhead because medical device sales require strong documentation, validation, and post-market compliance. Its Mississauga headquarters also adds rent, admin, legal, finance, and quality-system costs that do not fall much with volume.

These costs are a built-in part of the model, so scaling revenue is key to spreading them across more procedures and devices.

• Compliance and quality systems are fixed costs.
• Mississauga HQ adds corporate overhead.
• Legal and finance spend stays required.

Profound Medical Corp. uses training and installation fees to get hospitals live on TULSA-PRO, since onboarding is usually needed before clinical use. These fees can be billed separately or bundled, and they help cover site setup, staff training, and deployment support tied to each system sale.

In fiscal 2025, this stream remained directly linked to installed-system growth and is usually recognized as part of the launch cost for new clinical sites.

• Supports new hospital onboarding
• Can be separate or bundled
• Helps speed clinical adoption

Profound Medical Corp can create recurring revenue from consumables and accessories each time its systems are used, so this stream is smaller than the capital sale but can repeat across the installed base and lift lifetime customer value.

• Repeat use drives recurring sales
• Accessories are lower ticket than systems
• Installed base supports LTV growth

This matters because every procedure can add follow-on demand, helping revenue become less dependent on new system placements.